drugset / Trial / NCT07010159
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
Phase 2/3
Recruiting
165 enrolled
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals, Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Timeline
- Start
- 2025-07-25
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KPL-387 | Unknown | 100 mg | Subcutaneous |
| Subject | KPL-387 | Unknown | 300 mg | Subcutaneous |